New cancer drug LNF2105 enters first human trials

NCT ID NCT07661797

Not yet recruiting Disease control Sponsor: Shandong New Time Pharmaceutical Co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of standard options. The main goals are to check safety and find the right dose, while also looking for any signs that the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LNF2105 (an antibody-drug conjugate that targets Nectin-4 on cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors like bladder, breast, or lung cancer that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial, so the main goal is safety, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH ADVANCED SOLID TUMORS

More trials for these conditions

Other studies related to the condition(s) this trial covers.